Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Design Therapeutics ( (DSGN) ) has issued an announcement.
On January 29, 2026, Design Therapeutics, Inc. announced that board member Deepa Prasad had notified the company of her decision to resign from its Board of Directors, effective February 1, 2026. The departure results from conflict-avoidance policies tied to her newly appointed role at a major bank, indicating a governance-driven board change that may prompt the company to reassess its board composition and expertise mix.
The most recent analyst rating on (DSGN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
The score is held back primarily by weak financial performance (no revenue, persistent losses, and significant cash burn), partially offset by a strong balance sheet with minimal leverage. Technical indicators are supportive and lift the score, while valuation remains uncertain due to negative earnings and no dividend data.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Average Trading Volume: 425,370
Technical Sentiment Signal: Buy
Current Market Cap: $577M
Learn more about DSGN stock on TipRanks’ Stock Analysis page.